Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis

NCT05485155 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT05485155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2025
Completion date
January 31, 2027
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis